Search
GeneDx Holdings Corp
WGSAdd to Watchlist
39.686USD
+0.746+1.92%
Market hours （ET）Quotes delayed by 15 min
1.18BMarket Cap
LossP/E TTM
More Details of GeneDx Holdings Corp Company
GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.
GeneDx Holdings Corp Info
Ticker SymbolWGS
Company nameGeneDx Holdings Corp
IPO dateSep 04, 2020
CEOStueland (Katherine A)
Number of employees1000
Security typeOrdinary Share
Fiscal year-endSep 04
Address333 Ludlow Street
CitySTAMFORD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code06902
Phone18887291206
Websitehttps://sema4.com/
Ticker SymbolWGS
IPO dateSep 04, 2020
CEOStueland (Katherine A)
Company Executives of GeneDx Holdings Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Keith A. Meister
Mr. Keith A. Meister
Independent Director
Independent Director
4.44M
+99.55%
Mr. Joshua Ruch
Mr. Joshua Ruch
Independent Director
Independent Director
185.99K
-20.43%
Mr. Kevin Feeley
Mr. Kevin Feeley
Chief Financial Officer
Chief Financial Officer
34.94K
+0.28%
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Independent Director
Independent Director
26.33K
-25.95%
Mr. Jason Michael Ryan, CPA
Mr. Jason Michael Ryan, CPA
Chairman of the Board
Chairman of the Board
--
--
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Ms. Katherine A. Stueland
Ms. Katherine A. Stueland
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Bryan Dechairo
Dr. Bryan Dechairo
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Thomas Fuchs
Dr. Thomas Fuchs
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Keith A. Meister
Mr. Keith A. Meister
Independent Director
Independent Director
4.44M
+99.55%
Mr. Joshua Ruch
Mr. Joshua Ruch
Independent Director
Independent Director
185.99K
-20.43%
Mr. Kevin Feeley
Mr. Kevin Feeley
Chief Financial Officer
Chief Financial Officer
34.94K
+0.28%
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Independent Director
Independent Director
26.33K
-25.95%
Mr. Jason Michael Ryan, CPA
Mr. Jason Michael Ryan, CPA
Chairman of the Board
Chairman of the Board
--
--
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Patients with third party insurance
345.24M
80.75%
Institutional customers
70.07M
16.39%
Other
10.87M
2.54%
Self pay patients
1.36M
0.32%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Patients with third party insurance
345.24M
80.75%
Institutional customers
70.07M
16.39%
Other
10.87M
2.54%
Self pay patients
1.36M
0.32%
Shareholding Stats
Updated: 13 hours ago
Updated: 13 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Meister (Keith A)
14.95%
Corvex Management LP
14.93%
Icahn School of Medicine at Mount Sinai
4.63%
OPKO Health Inc
4.62%
Westfield Capital Management Company, L.P.
4.61%
Other
56.27%
Shareholders
Shareholders
Proportion
Meister (Keith A)
14.95%
Corvex Management LP
14.93%
Icahn School of Medicine at Mount Sinai
4.63%
OPKO Health Inc
4.62%
Westfield Capital Management Company, L.P.
4.61%
Other
56.27%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
35.13%
Investment Advisor
33.09%
Hedge Fund
32.91%
Corporation
10.37%
Research Firm
6.51%
Individual Investor
1.81%
Pension Fund
0.40%
Bank and Trust
0.39%
Sovereign Wealth Fund
0.23%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
456
30.28M
113.16%
--
2026Q1
549
32.98M
111.70%
+333.95K
2025Q4
500
30.62M
105.95%
-3.52M
2025Q3
446
32.52M
112.51%
-918.42K
2025Q2
397
34.23M
119.24%
+1.02M
2025Q1
398
32.79M
115.46%
-47.86K
2024Q4
341
29.17M
104.22%
+1.72M
2024Q3
289
26.18M
97.50%
+377.48K
2024Q2
262
24.98M
95.33%
+588.25K
2024Q1
260
22.13M
86.19%
+1.41M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Corvex Management LP
3.06M
10.44%
--
--
Dec 31, 2025
Icahn School of Medicine at Mount Sinai
1.37M
4.69%
-1.35M
-49.50%
Feb 21, 2025
OPKO Health Inc
1.37M
4.68%
-800.83K
-36.88%
Nov 20, 2024
Westfield Capital Management Company, L.P.
1.02M
3.48%
+474.17K
+87.15%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
1.34M
4.58%
+25.70K
+1.95%
Dec 31, 2025
ARK Investment Management LLC
604.56K
2.06%
+157.58K
+35.25%
Dec 31, 2025
Goldman Sachs & Company, Inc.
1.02M
3.48%
+17.80K
+1.78%
Dec 31, 2025
Summit Partners Public Asset Management, LLC
920.59K
3.14%
+97.02K
+11.78%
Dec 31, 2025
Oracle Investment Management, Inc.
884.65K
3.02%
-5.30K
-0.60%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Global X Genomics & Biotechnology ETF
3.84%
Franklin Genomic Advancements ETF
3.47%
Clough Hedged Equity ETF
2.89%
Clough Select Equity ETF
2.65%
State Street SPDR S&P Health Care Services ETF
2.27%
Harbor Health Care ETF
1.85%
Innovator IBD Breakout Opportunities ETF
1.52%
ARK Genomic Revolution ETF
1.29%
Main Thematic Innovation ETF
1.29%
Invesco Dorsey Wright Healthcare Momentum ETF
1.18%
View more
Global X Genomics & Biotechnology ETF
Proportion3.84%
Franklin Genomic Advancements ETF
Proportion3.47%
Clough Hedged Equity ETF
Proportion2.89%
Clough Select Equity ETF
Proportion2.65%
State Street SPDR S&P Health Care Services ETF
Proportion2.27%
Harbor Health Care ETF
Proportion1.85%
Innovator IBD Breakout Opportunities ETF
Proportion1.52%
ARK Genomic Revolution ETF
Proportion1.29%
Main Thematic Innovation ETF
Proportion1.29%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.18%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Date
Ex-dividend Date
Type
Ratio
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
